Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP0202 formulations versus Prevnar 13 in healthy toddlers and infants
2021-002146-33Phase 2
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SP0202 and Prevnar 13 in pneumococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Number of participants reporting immediate adverse events.
02
Drugs
SP0202Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2021-002146-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002146-33.